NCT06823713View on ClinicalTrials.gov

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

August 29, 2028

Study Completion Date

November 29, 2028

Conditions
End-stage Liver Disease (ESLD)Cirrhosis, LiverCirrhosis, DecompensatedLiver DiseasesFibrosis and Cirrhosis of LiverDecompensated Liver CirrhosisDecompensated CirrhosisSteatotic Liver Disease
Interventions
DRUG

RTX001

RTX001 is an autologous engineered regenerative macrophage cell therapy

Trial Locations (14)

14004

RECRUITING

Hospital Universitario Reina Sofía, Córdoba

28007

RECRUITING

Hospital General Universitario Gregorio Marañon, Madrid

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

41013

RECRUITING

Hospital Universitario Virgen del Rocío, Seville

08035

NOT_YET_RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

BS2 8HW

RECRUITING

Bristol Royal Infirmary, Bristol

EH16 4SA

RECRUITING

Royal Infirmary of Edinburgh, Edinburgh

G4 0SF

NOT_YET_RECRUITING

Glasgow Royal Infirmary, Glasgow

L7 8YE

RECRUITING

Royal Liverpool University Hospital, Liverpool

SE5 9RS

RECRUITING

King's College Hospital, London

SW17 0QT

RECRUITING

St George's Hospital, London

W2 1NY

RECRUITING

St Mary's Hospital, London

NG5 1PB

NOT_YET_RECRUITING

Nottingham University Hospital, Nottingham

All Listed Sponsors
lead

Resolution Therapeutics Limited

NETWORK